IOL Chemicals & Pharmaceuticals Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

- Company expects mid-teen to high-teen revenue growth for FY 2027 and over the medium term. - EBITDA margin guidance for FY 2027 is around 14% to 14.5%. - PAT growth anticipated in the range of 15% to 20%, maintaining previous guidance. - Capacity utilization improvements and operational efficiencies to support margin expansion. - Growth driven by higher contribution from non-Ibuprofen portfolio and increased exports, especially to Europe. - Capex of around INR 200-250 crores annually planned for the new greenfield site, with total outlay of INR 1,200-1,400 crores over 4-5 years to support scaled growth. - The company prefers to focus on yearly performance rather than quarterly, considering global market dynamism. Overall, steady growth with improved earnings and operating margins is expected, driven by operational efficiencies and product mix expansion.

The transcript provided does not explicitly mention the current or expected order book or pending orders for IOL Chemicals and Pharmaceuticals Limited. However, relevant points related to company outlook and growth include: - The company is targeting around INR 2,700 crores in revenue for FY 2027, with mid-teen revenue growth expected annually. - Capacity utilization is high across key products (around 85%-95% for most products; paracetamol capacity utilization expected to rise from 55% to 75%). - Export share, especially for non-ibuprofen products, is expected to increase to around 25% in FY 2027. - The new greenfield project on 100 acres is planned with phased capex of INR 1,200 to 1,400 crores over 4 to 5 years to support future growth. - The company remains confident about maintaining momentum and growth over the next few quarters despite global uncertainties. No specific details about outstanding order book or pending orders are disclosed.